Validation of a Host Response Assay, SeptiCyte LAB, for Discriminating Sepsis from Systemic Inflamma...
Validation of a Host Response Assay, SeptiCyte LAB, for Discriminating Sepsis from Systemic Inflammatory Response Syndrome in the ICU
About this item
Full title
Author / Creator
Miller, 3rd, Russell R , Lopansri, Bert K , Burke, John P , Levy, Mitchell , Opal, Steven , Rothman, Richard E , D'Alessio, Franco R , Sidhaye, Venkataramana K , Aggarwal, Neil R , Balk, Robert , Greenberg, Jared A , Yoder, Mark , Patel, Gourang , Gilbert, Emily , Afshar, Majid , Parada, Jorge P , Martin, Greg S , Esper, Annette M , Kempker, Jordan A , Narasimhan, Mangala , Tsegaye, Adey , Hahn, Stella , Mayo, Paul , van der Poll, Tom , Schultz, Marcus J , Scicluna, Brendon P , Klein Klouwenberg, Peter , Rapisarda, Antony , Seldon, Therese A , McHugh, Leo C , Yager, Thomas D , Cermelli, Silvia , Sampson, Dayle , Rothwell, Victoria , Newman, Richard , Bhide, Shruti , Fox, Brian A , Kirk, James T , Navalkar, Krupa , Davis, Roy F , Brandon, Roslyn A and Brandon, Richard B
Publisher
United States: American Thoracic Society
Journal title
Language
English
Formats
Publication information
Publisher
United States: American Thoracic Society
Subjects
More information
Scope and Contents
Contents
A molecular test to distinguish between sepsis and systemic inflammation of noninfectious etiology could potentially have clinical utility.
This study evaluated the diagnostic performance of a molecular host response assay (SeptiCyte LAB) designed to distinguish between sepsis and noninfectious systemic inflammation in critically ill adults.
The study employed a prospective, observational, noninterventional design and recruited a heterogeneous cohort of adult critical care patients from seven sites in the United States (n = 249). An additional group of 198 patients, recruited in the large MARS (Molecular Diagnosis and Risk Stratification of Sepsis) consortium trial in the Netherlands ( www.clinicaltrials.gov identifier NCT01905033), was also tested and analyzed, making a grand total of 447 patients in our study. The performance of SeptiCyte LAB was compared with retrospective physician diagnosis by a panel of three experts.
In receiver operating characteristic curve analysis, SeptiCyte LAB had an estimated area under the curve of 0.82-0.89 for...
Alternative Titles
Full title
Validation of a Host Response Assay, SeptiCyte LAB, for Discriminating Sepsis from Systemic Inflammatory Response Syndrome in the ICU
Authors, Artists and Contributors
Author / Creator
Lopansri, Bert K
Burke, John P
Levy, Mitchell
Opal, Steven
Rothman, Richard E
D'Alessio, Franco R
Sidhaye, Venkataramana K
Aggarwal, Neil R
Balk, Robert
Greenberg, Jared A
Yoder, Mark
Patel, Gourang
Gilbert, Emily
Afshar, Majid
Parada, Jorge P
Martin, Greg S
Esper, Annette M
Kempker, Jordan A
Narasimhan, Mangala
Tsegaye, Adey
Hahn, Stella
Mayo, Paul
van der Poll, Tom
Schultz, Marcus J
Scicluna, Brendon P
Klein Klouwenberg, Peter
Rapisarda, Antony
Seldon, Therese A
McHugh, Leo C
Yager, Thomas D
Cermelli, Silvia
Sampson, Dayle
Rothwell, Victoria
Newman, Richard
Bhide, Shruti
Fox, Brian A
Kirk, James T
Navalkar, Krupa
Davis, Roy F
Brandon, Roslyn A
Brandon, Richard B
Identifiers
Primary Identifiers
Record Identifier
TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_6835074
Permalink
https://devfeature-collection.sl.nsw.gov.au/record/TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_6835074
Other Identifiers
ISSN
1073-449X
E-ISSN
1535-4970
DOI
10.1164/rccm.201712-2472OC
